|
|
Post by jurystillout on Oct 21, 2015 14:15:47 GMT -5
What I was trying to get at in my original post was more along the lines of trying to estimate the original expectations as to afrezza sales. I felt the requirement that the contract couldn't be cancelled without 2 years notice was pretty extreme, and MNKD agreeing to it meant it must have been pretty confident about its estimated need at the time. So I just wondered how many afrezza cartridges could be produced with 24 million euros worth of insulin and how that compares with the number of cartridges they are actually selling. rrtzmd you're getting warm, just go a little further and you'll come to the same conclusion that I have. The amphistar deal is going to go down as one of the many big blunders MNKD management has made with this product. They made an obscene commitment when they had no basis for volume and they did this just prior to signing a deal with SNY. I understand the need to make sure they have access to materials for production however all along we've been told they have inventory from the pfizer insulin purchase. Even after making the commitment they didn't address how this commitment would be met while writing the SNY agreement. Again, outstanding product, tremendous potential with incompetent management at the helm. |
|
|
|
Post by esstan2001 on Oct 21, 2015 14:43:21 GMT -5
What I was trying to get at in my original post was more along the lines of trying to estimate the original expectations as to afrezza sales. I felt the requirement that the contract couldn't be cancelled without 2 years notice was pretty extreme, and MNKD agreeing to it meant it must have been pretty confident about its estimated need at the time. So I just wondered how many afrezza cartridges could be produced with 24 million euros worth of insulin and how that compares with the number of cartridges they are actually selling. rrtzmd you're getting warm, just go a little further and you'll come to the same conclusion that I have. The amphistar deal is going to go down as one of the many big blunders MNKD management has made with this product. They made an obscene commitment when they had no basis for volume and they did this just prior to signing a deal with SNY. I understand the need to make sure they have access to materials for production however all along we've been told they have inventory from the pfizer insulin purchase. Even after making the commitment they didn't address how this commitment would be met while writing the SNY agreement. Again, outstanding product, tremendous potential with incompetent management at the helm. The obligation is only an issue during the slow ramp (2015) and hopefully not a drag once we get going in 2016. And it's not one that will break the bank so long as sales make it onto that ramp within a reasonable time frame. Also, at this stage MNKD does not have FDA permission to use the Pfizer insulin, although they continue to maintain and monitor it for potential submission later as an FDA approved source of supply. |
|
|
|
Post by LongMNKD on Oct 22, 2015 1:11:44 GMT -5
Considering this job posting has not been removed... seems odd considering Sanofi's supposed "hiring freeze" they have in force right now. Unless of course, the article on the hiring freeze was completely bogus as most of us suspect.
|
|
|
|
Post by cathode on Oct 22, 2015 8:07:21 GMT -5
Considering this job posting has not been removed... seems odd considering Sanofi's supposed "hiring freeze" they have in force right now. Unless of course, the article on the hiring freeze was completely bogus as most of us suspect. Has anyone here actually looked at the job posting? It is for Toujeo, not Afrezza. |
|
|
|
Post by ezrasfund on Oct 22, 2015 8:51:48 GMT -5
The issues of insurance and final cost to the patient are obscuring the fact that Afrezza is only slightly more expensive than other RAA's. Remember that while Afrezza is priced at a slight premium, even at the same cost as competing meal time insulins it would still be very profitable. And we all know that most drugs are less expensive in the rest of the world than they are in the US.
|
|
|
|
Post by suebeeee1 on Oct 22, 2015 9:56:26 GMT -5
at this moment, SNY and MNKD both are in quiet periods prior to earnings. (What ever that means.) Earnings? No earnings? When are they NOT in a quiet period? |
|
|
|
Post by peppy on Oct 22, 2015 10:04:55 GMT -5
at this moment, SNY and MNKD both are in quiet periods prior to earnings. (What ever that means.) Earnings? No earnings? When are they NOT in a quiet period? At the aegis conference, matt said, "we are in a quiet period." |
|
|
|
Post by suebeeee1 on Oct 22, 2015 11:45:04 GMT -5
Earnings? No earnings? When are they NOT in a quiet period? At the aegis conference, matt said, "we are in a quiet period." Methinks perhaps they have fallen asleep? |
|
|
|
Post by bradleysbest on Oct 22, 2015 11:54:05 GMT -5
Quiet period by choice?
|
|
|
|
Post by rrtzmd on Oct 22, 2015 13:24:16 GMT -5
rrtzmd you're getting warm, just go a little further and you'll come to the same conclusion that I have. The amphistar deal is going to go down as one of the many big blunders MNKD management has made with this product. They made an obscene commitment when they had no basis for volume and they did this just prior to signing a deal with SNY. I understand the need to make sure they have access to materials for production however all along we've been told they have inventory from the pfizer insulin purchase. Even after making the commitment they didn't address how this commitment would be met while writing the SNY agreement. Again, outstanding product, tremendous potential with incompetent management at the helm. The obligation is only an issue during the slow ramp (2015) and hopefully not a drag once we get going in 2016. And it's not one that will break the bank so long as sales make it onto that ramp within a reasonable time frame. Also, at this stage MNKD does not have FDA permission to use the Pfizer insulin, although they continue to maintain and monitor it for potential submission later as an FDA approved source of supply. I was totally unaware of this: "Also, at this stage MNKD does not have FDA permission to use the Pfizer insulin, although they continue to maintain and monitor it for potential submission later as an FDA approved source of supply." Is that written in any official document or press release? Why hasn't the FDA approved it? Can approval be expected at some point? How old is it now? If they can't use it, can they sell it? |
|
|
|
Post by esstan2001 on Oct 22, 2015 13:37:47 GMT -5
I was totally unaware of this: "Also, at this stage MNKD does not have FDA permission to use the Pfizer insulin, although they continue to maintain and monitor it for potential submission later as an FDA approved source of supply." Is that written in any official document or press release? >>>2014 annual report Why hasn't the FDA approved it? >>>Mannkind must perform some bio-equivalence testing that takes resources, and they do not need it at this point since they ran the trials and got FDA appvl using the Amphistar sourced insulin Can approval be expected at some point? ... >>>Maybe How old is it now? ... >>>7ish years If they can't use it, can they sell it? ...>>>maybe |
|
|
|
Post by kball on Oct 22, 2015 14:14:17 GMT -5
at this moment, SNY and MNKD both are in quiet periods prior to earnings. (What ever that means.) Earnings? No earnings? When are they NOT in a quiet period?ANSWER: When they are in the silent period and the mute period. It seems to oscillate primarily between these three. |
|
|
|
Post by liane on Oct 22, 2015 14:49:38 GMT -5
The Pfizer insulin can only be used for inhaled format per contractual agreement. So - not too many potential buyers.
|
|
